Findings reveal Bifidobacterium adolescentis reduces weight loss in mice with DSS-induced colitis, indicating its therapeutic potential for inflammatory bowel disease.
Key Points
To evaluate the potential of Bifidobacterium adolescentis in managing DSS-induced colitis.
Isolation of Lactobacillus and Bifidobacterium strains from healthy human feces
Oral administration of Bifidobacterium adolescentis to mice over two weeks
Measurement of IL-10 production and gut inflammation levels
Bifidobacterium adolescentis enhanced IL-10 production in vitro
Reduced weight loss and DSS-induced colon inflammation in mice
Identified CD19?CD11b? B1 cells as the main source of IL-10 post-exposure